Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Summary

Evaluate the safety and tolerability of AMG 553 in adult and adolescent subjects with FLT3-positive R/R AML. Determine the maximum tolerated cell dose (MTCD) or recommended phase 2 cell dose (RP2CD) of AMG 553.

Timeline

Start

2023-03-13

Primary completion

2030-08-07

Completion

2030-08-07

Outcome

Outcome not reported

Stopped (Business): “Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.”

Drugs

Indications